Viking Therapeutics reports 22% placebo-adjusted weight loss in VK2735 obesity study
Viking Therapeutics (NASDAQ:VKTX) announced positive topline results from a 33-week clinical study evaluating VK2735, its investigational GLP-1/GIP receptor agonist being developed for obesity treatment.










